Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of sunitinib malate (SU011248) in the treatment of patients with malignant gastrointestinal stromal tumor (GIST) previously treated by imatinib mesylate

Next Previous
X
Search
Trial Profile

A phase I/II study of sunitinib malate (SU011248) in the treatment of patients with malignant gastrointestinal stromal tumor (GIST) previously treated by imatinib mesylate

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 10 Jun 2020 Results (n=350) of simulation study from four clinical trials: study 1004, study 1047, study 1045 and study 013 assessing effects of dose increase on pharmacodynamic biomarkers can increase OS and retaining an acceptable safety profile published in the Clinical Cancer Research
    • 17 Nov 2009 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov
    • 17 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top